Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen Inc    BIIB

BIOGEN INC (BIIB)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/16/2017 02/17/2017 02/21/2017 02/22/2017 02/23/2017 Date
290.13(c) 288.94(c) 286.9(c) 287.63(c) 284.75(c) Last
1 834 892 2 022 911 1 471 212 1 045 957 1 418 866 Volume
-0.86% -0.41% -0.71% +0.25% -1.00% Change
More quotes
Financials ($)
Sales 2017 11 287 M
EBIT 2017 6 114 M
Net income 2017 3 973 M
Debt 2017 610 M
Yield 2017 -
Sales 2018 11 997 M
EBIT 2018 6 477 M
Net income 2018 4 376 M
Finance 2018 893 M
Yield 2018 -
P/E ratio 2017 15,38
P/E ratio 2018 13,73
EV / Sales2017 5,50x
EV / Sales2018 5,05x
Capitalization 61 492 M
More Financials
Company
Biogen, Inc. is a global biotechnology company, which focuses on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders.Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for... 
Sector
Pharmaceuticals
Calendar
04/27Earnings Release
More about the company
Surperformance© ratings of Biogen Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOGEN INC
02/15 BIOGEN : to Present at the 2017 RBC Capital Markets Global Healthcare Conference
02/07 BIOGEN : to Present at the Leerink Partners 6th Annual Global Healthcare Confere..
02/02 BIOGEN INC : Spin off
02/01 BIOGEN : Completes Separation of Global Hemophilia Business, Bioverativ
01/26DJBIOGEN : Profit Skids, Revenue Grows Less Than Expected
01/26 BIOGEN : Reports 2016 Revenues of $11.4 Billion
01/23BIOGEN INC : annual earnings release
01/17 BIOGEN FOURTH QUARTER AND YEAR END 2 : 00 am on January 26, 2017
01/17 SIEMENS HEALTHINEERS : and Biogen Announce Agreement to Jointly Develop New MRI ..
01/17DJBIOGEN : Reaches Settlement and License Agreement for MS Drug
More news
Sector news : Biopharmaceuticals
12:59a Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
02/23DJGlaxoSmithKline Reports Positive Study Results for Asthma Drug
02/23DJPURETECH HEALTH : Appoints Atul Pande as Chief Medical Officer
02/23DJBAYER : Financing Plan Will Raise Equity First Then Bonds -- WSJ
More sector news : Biopharmaceuticals
4-Traders Strategies on BIOGEN INC 
2014Back on a stimulating support
2013The bullish trend is not over
More Strategies
Latest Tweets
02/23Biogen Inc $BIIB Stock Rating Upgraded by TheStreet  
02/23Breaking Down The Multiple Sclerosis 2017 Formularies: 'Stability Fares Well .. 
02/23A few Bios acting well today: ACAD, BLUE and Biogen spinoff BIVV. 
02/23Merrill Lynch sees top large cap Biotech Stocks being the cheapest they have .. 
02/22ICYMI: @PhRMA, @LillyPad, @Biogen and others discuss new era of medicine at #..
2
More tweets
Qtime:122
News from SeekingAlpha
02/23 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2016 Update
02/21 This Biotech ETF Looks Primed To Rally Again
02/20 Tracking John Paulson's Paulson & Company Portfolio - Q4 2016 Update
02/19 Tracking Jeffrey Ubben's ValueAct Portfolio - Q4 2016 Update
02/17 Can Anything Be Learned From Alzheimer's Drug Failures?
Advertisement
Chart BIOGEN INC
Duration : Period :
Biogen Inc Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Full-screen chart
Technical analysis trends BIOGEN INC
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 322 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Spyridon Artavanis-Tsakonas Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC10.06%61 492
CSL LIMITED20.04%42 089
ALEXION PHARMACEUTICAL..6.93%29 299
BIOMARIN PHARMACEUTICA..7.79%15 357
GRIFOLS SA11.89%14 019
3SBIO INC19.87%2 976
More Results